Jerry Mo

Background

About Jerry Mo

Experienced Chief Financial Officer with a demonstrated history of working in the biotechnology industry. Skilled in Mergers & Acquisitions (M&A), Financial Accounting, Accounting, Treasury Management, and Cash Management. Strong finance professional with an Accounting and Data Processing focus in Accounting and Computer Science from the University of Leeds. Achievements in the past 17 years: As Chief Financial Officer- Finance of CK Life Sciences Int'l (Holdings) Inc Reporting under the Hong Kong Stock Exchange listing rules and HK GAAP, periodic roadshows & investors’ conferences/meetings in Hong Kong. Results announcement made in mid-March for a Dec year-end company. Financial management & planning, monthly group consolidation, with subsidiaries in Asia, Australia, the US, and Canada. Monthly management reporting completed within 5 days after month-end. Tax compliance & planning, especially -HK, Canada, US, Australia & PRC tax planning -Transfer pricing arrangements with subsidiaries in HK, Canada, the US, Australia, and the PRC. Setting up and maintaining: 1) US tax structure via European Holding companies – effective tax rate of 6% vs 23%. Annual savings of HK$15m in 2021. 2) Australian tax structure – financing using inter-company loans under thin cap rules. Effective tax rate of 22% vs 30%. Annual savings of HK$25m in 2021. Managed an Australian Tax Office audit, which covered tax returns from 2008 to 2014. This was successfully completed in 2019 with the following results: • Additional tax payment of HK$46m • No penalty and penalty rate of interest imposed • Settlement represented only 26% of the original tax shortfall claimed by the ATO Treasury management, including the management of a loan portfolio of HK$5.6 billion (2022), negotiated favorable loan covenants and interest rates to support various acquisitions of the Group. Liaised with investors, lawyers, auditors, bankers, and tax consultants Leader in the selection and implementation of an ERP (Axaptor) solution for the Group. Participate in merger and acquisition discussions with potential acquisition targets in Europe, the US, Canada, and Australia. Arrange due diligence support with legal and financial advisors. Successful acquisition of various companies over the years, expanding the operations of the Group, providing profit growth. The total value of companies acquired was around HK$8 Billion, including the Nutraceutical Businesses in the US and Australia, Salt, Vineyard, and Agrichemical and fertilizer Businesses in Australia, R&D companies in the US and Canada.